In China, a new drug goes through a multi-step approval process. It starts with preclinical studies, followed by clinical trials in three phases. After successful trials, the drug is submitted for regulatory review and approval. The National Medical Products Administration (NMPA) evaluates the drug’s safety, efficacy, and quality. If approved, it can be marketed and sold in China.
